WO2022186648A1 - 쿠마린산을 포함하는 항콕시듐용 조성물 및 이의 용도 - Google Patents
쿠마린산을 포함하는 항콕시듐용 조성물 및 이의 용도 Download PDFInfo
- Publication number
- WO2022186648A1 WO2022186648A1 PCT/KR2022/003072 KR2022003072W WO2022186648A1 WO 2022186648 A1 WO2022186648 A1 WO 2022186648A1 KR 2022003072 W KR2022003072 W KR 2022003072W WO 2022186648 A1 WO2022186648 A1 WO 2022186648A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eimeria
- ppm
- coumaric acid
- coccidiosis
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 239000002253 acid Substances 0.000 title claims abstract description 60
- 230000001165 anti-coccidial effect Effects 0.000 title claims abstract description 19
- 208000003495 Coccidiosis Diseases 0.000 claims abstract description 70
- 206010023076 Isosporiasis Diseases 0.000 claims abstract description 70
- 150000003839 salts Chemical class 0.000 claims abstract description 51
- 230000035755 proliferation Effects 0.000 claims abstract description 16
- 230000029142 excretion Effects 0.000 claims abstract description 9
- 241000223924 Eimeria Species 0.000 claims description 139
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 claims description 41
- 230000003902 lesion Effects 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- KKSDGJDHHZEWEP-SNAWJCMRSA-N trans-3-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=CC(O)=C1 KKSDGJDHHZEWEP-SNAWJCMRSA-N 0.000 claims description 20
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 claims description 19
- KKSDGJDHHZEWEP-UHFFFAOYSA-N m-hydroxycinnamic acid Natural products OC(=O)C=CC1=CC=CC(O)=C1 KKSDGJDHHZEWEP-UHFFFAOYSA-N 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- PMOWTIHVNWZYFI-AATRIKPKSA-N trans-2-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1O PMOWTIHVNWZYFI-AATRIKPKSA-N 0.000 claims description 12
- 230000000842 anti-protozoal effect Effects 0.000 claims description 11
- PMOWTIHVNWZYFI-UHFFFAOYSA-N o-Coumaric acid Natural products OC(=O)C=CC1=CC=CC=C1O PMOWTIHVNWZYFI-UHFFFAOYSA-N 0.000 claims description 9
- 230000002550 fecal effect Effects 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- 239000003674 animal food additive Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000004580 weight loss Effects 0.000 claims description 6
- 239000003904 antiprotozoal agent Substances 0.000 claims description 5
- 238000001764 infiltration Methods 0.000 claims description 5
- 230000008595 infiltration Effects 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 4
- 241000304695 Eimeria sp. Species 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 22
- 208000015181 infectious disease Diseases 0.000 abstract description 18
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 230000035515 penetration Effects 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 8
- 210000003250 oocyst Anatomy 0.000 abstract description 8
- 210000003608 fece Anatomy 0.000 abstract description 7
- 241000287828 Gallus gallus Species 0.000 description 41
- 241000283973 Oryctolagus cuniculus Species 0.000 description 37
- 239000013642 negative control Substances 0.000 description 29
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 28
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 23
- 235000013330 chicken meat Nutrition 0.000 description 17
- 229960000956 coumarin Drugs 0.000 description 17
- 241000283707 Capra Species 0.000 description 16
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 15
- 241000283705 Capra hircus Species 0.000 description 14
- 239000004189 Salinomycin Substances 0.000 description 14
- 235000001671 coumarin Nutrition 0.000 description 14
- 229960001548 salinomycin Drugs 0.000 description 14
- 235000019378 salinomycin Nutrition 0.000 description 14
- 238000011081 inoculation Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- ZSZFUDFOPOMEET-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl ZSZFUDFOPOMEET-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 241001494479 Pecora Species 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 229960000248 diclazuril Drugs 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229940074391 gallic acid Drugs 0.000 description 11
- 235000004515 gallic acid Nutrition 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 210000003046 sporozoite Anatomy 0.000 description 11
- 241000286209 Phasianidae Species 0.000 description 10
- 239000002131 composite material Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 240000008025 Alternanthera ficoidea Species 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 8
- 241000223932 Eimeria tenella Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 7
- -1 Amphurolium Chemical compound 0.000 description 6
- 241000288147 Meleagris gallopavo Species 0.000 description 6
- 229940124536 anticoccidial agent Drugs 0.000 description 6
- 239000003224 coccidiostatic agent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 241000223931 Eimeria acervulina Species 0.000 description 5
- 241000288047 Phasianus colchicus Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 241000272517 Anseriformes Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 241000223934 Eimeria maxima Species 0.000 description 4
- 241001485851 Eimeria perforans Species 0.000 description 4
- 241000499544 Eimeria praecox Species 0.000 description 4
- 241000004492 Eimeria vermiformis Species 0.000 description 4
- 241001418410 Lasiurus borealis Species 0.000 description 4
- 241001515330 Myodes gapperi Species 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 235000021051 daily weight gain Nutrition 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000252229 Carassius auratus Species 0.000 description 3
- 241001609213 Carassius carassius Species 0.000 description 3
- 241000499566 Eimeria brunetti Species 0.000 description 3
- 241001485849 Eimeria coecicola Species 0.000 description 3
- 241001327860 Eimeria dispersa Species 0.000 description 3
- 241001327857 Eimeria gallopavonis Species 0.000 description 3
- 244000309702 Eimeria hagani Species 0.000 description 3
- 241001452562 Eimeria innocua Species 0.000 description 3
- 241001485852 Eimeria magna Species 0.000 description 3
- 241001485868 Eimeria media Species 0.000 description 3
- 241000179199 Eimeria mitis Species 0.000 description 3
- 241000530449 Eimeria mivati Species 0.000 description 3
- 241000499563 Eimeria necatrix Species 0.000 description 3
- 241000349703 Eimeria papillata Species 0.000 description 3
- 241001485850 Eimeria piriformis Species 0.000 description 3
- 241001203535 Eimeria purpureicephali Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108091023242 Internal transcribed spacer Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001416523 Lasiorhinus latifrons Species 0.000 description 3
- 241000270322 Lepidosauria Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241001075751 Notamacropus Species 0.000 description 3
- 241001502076 Oryzomys palustris Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241001125039 Pipistrellus Species 0.000 description 3
- 241000282330 Procyon lotor Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 241001416177 Vicugna pacos Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 235000004883 caffeic acid Nutrition 0.000 description 3
- 229940074360 caffeic acid Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 235000001785 ferulic acid Nutrition 0.000 description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 3
- 229940114124 ferulic acid Drugs 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000576607 Amphisbaena manni Species 0.000 description 2
- 241000510008 Amphisbaenia Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000124815 Barbus barbus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000287929 Colinus virginianus Species 0.000 description 2
- 241000343737 Columbina talpacoti Species 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000289819 Eimeria adenoeides Species 0.000 description 2
- 241000011819 Eimeria ahsata Species 0.000 description 2
- 241000406205 Eimeria alabamensis Species 0.000 description 2
- 241001043461 Eimeria arloingi Species 0.000 description 2
- 241000223933 Eimeria bovis Species 0.000 description 2
- 241000059290 Eimeria christenseni Species 0.000 description 2
- 241000146358 Eimeria crandallis Species 0.000 description 2
- 241000221511 Eimeria exigua Species 0.000 description 2
- 241001662550 Eimeria falciformis Species 0.000 description 2
- 241000354183 Eimeria ferrisi Species 0.000 description 2
- 241001485867 Eimeria flavescens Species 0.000 description 2
- 241001129961 Eimeria hirci Species 0.000 description 2
- 241001485866 Eimeria intestinalis Species 0.000 description 2
- 241000221513 Eimeria irresidua Species 0.000 description 2
- 241000698073 Eimeria krijgsmanni Species 0.000 description 2
- 241000675211 Eimeria leucisci Species 0.000 description 2
- 241001223388 Eimeria macusaniensis Species 0.000 description 2
- 241001452550 Eimeria meleagridis Species 0.000 description 2
- 241001278028 Eimeria meleagrimitis Species 0.000 description 2
- 241000496472 Eimeria myoxi Species 0.000 description 2
- 241000179200 Eimeria nieschulzi Species 0.000 description 2
- 241000059291 Eimeria ninakohlyakimovae Species 0.000 description 2
- 241000146360 Eimeria ovinoidalis Species 0.000 description 2
- 241000349705 Eimeria separata Species 0.000 description 2
- 241001485873 Eimeria stiedai Species 0.000 description 2
- 241000031785 Eimeria weybridgensis Species 0.000 description 2
- 241001218082 Eimeria zuernii Species 0.000 description 2
- 241000520639 Eliomys quercinus Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 235000019733 Fish meal Nutrition 0.000 description 2
- 241001137351 Fratercula arctica Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000282852 Lama guanicoe Species 0.000 description 2
- 241000251479 Lepidosiren paradoxa Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 241000283868 Oryx Species 0.000 description 2
- 241001531354 Oryx leucoryx Species 0.000 description 2
- 241000288049 Perdix perdix Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000608595 Pipistrellus kuhlii Species 0.000 description 2
- 241000385511 Purpureicephalus spurius Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 241000201908 Scardafella squammata Species 0.000 description 2
- 241000269319 Squalius cephalus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000422865 Urocitellus armatus Species 0.000 description 2
- 241000282840 Vicugna vicugna Species 0.000 description 2
- 241000289674 Vombatidae Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000011681 asexual reproduction Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 208000027503 bloody stool Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- PMOWTIHVNWZYFI-WAYWQWQTSA-N cis-2-coumaric acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1O PMOWTIHVNWZYFI-WAYWQWQTSA-N 0.000 description 2
- KKSDGJDHHZEWEP-PLNGDYQASA-N cis-3-coumaric acid Chemical compound OC(=O)\C=C/C1=CC=CC(O)=C1 KKSDGJDHHZEWEP-PLNGDYQASA-N 0.000 description 2
- NGSWKAQJJWESNS-UTCJRWHESA-N cis-4-coumaric acid Chemical compound OC(=O)\C=C/C1=CC=C(O)C=C1 NGSWKAQJJWESNS-UTCJRWHESA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000004467 fishmeal Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000002555 ionophore Substances 0.000 description 2
- 230000000236 ionophoric effect Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 230000014639 sexual reproduction Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- BOBATFKNMFWLFG-UHFFFAOYSA-N 2-amino-2-cyano-n-methylacetamide Chemical compound CNC(=O)C(N)C#N BOBATFKNMFWLFG-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- MMOPREBWKCZVPO-UHFFFAOYSA-N 3-(4-hydroxyphenyl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1.OC(=O)C=CC1=CC=C(O)C=C1 MMOPREBWKCZVPO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000795282 Acanthocercus yemensis Species 0.000 description 1
- 101150100998 Ace gene Proteins 0.000 description 1
- 241000509639 Agama Species 0.000 description 1
- 241001476469 Agama agama Species 0.000 description 1
- 241000269328 Amphibia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000224482 Apicomplexa Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000251475 Dipnoi Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000283899 Gazella Species 0.000 description 1
- 241000983635 Gazella cuvieri Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000240923 Graphiurus ocularis Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 241001416524 Lasiorhinus Species 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001508691 Martes zibellina Species 0.000 description 1
- 241001125776 Melanochromis auratus Species 0.000 description 1
- 241001529466 Muscardinus avellanarius Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- MTUSZNHPVPZEGR-IPZCTEOASA-N OC1=C(/C=C/C(=O)O)C=CC=C1.C(C=CC=1C(=CC=CC1)O)(=O)O Chemical compound OC1=C(/C=C/C(=O)O)C=CC=C1.C(C=CC=1C(=CC=CC1)O)(=O)O MTUSZNHPVPZEGR-IPZCTEOASA-N 0.000 description 1
- 241000219233 Oreochromis aureus Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000609786 Oryx dammah Species 0.000 description 1
- 241000323779 Oryzomys couesi Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000283140 Phoca Species 0.000 description 1
- 241000283150 Phoca vitulina Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000975797 Polylepis Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000511372 Pseudochondrostoma polylepis Species 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- 241000700161 Rattus rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 241000392570 Squalius cephalus cabeda Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 240000003294 Thysanolaena latifolia Species 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241001147103 Vombatus Species 0.000 description 1
- 241001147098 Vombatus ursinus Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000000084 barbel Anatomy 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical class C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- XOIQMTLWECTKJL-FBZUZRIGSA-M sodium;(2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-ethyl-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoate Chemical compound [Na+].C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C([O-])=O)O2 XOIQMTLWECTKJL-FBZUZRIGSA-M 0.000 description 1
- NIUFFODHMKLSCH-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(6-chloropyrazin-2-yl)azanide Chemical compound [Na+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=CN=CC(Cl)=N1 NIUFFODHMKLSCH-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 229960003097 sulfaquinoxaline Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960000898 toltrazuril Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/50—Livestock or poultry management
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/807—Poultry or ruminant feed
Definitions
- the present application relates to a composition for anticoccidium containing coumaric acid and/or a salt thereof, and a use thereof.
- Coccidiosis is an intestinal-related disease caused by a protozoan parasite belonging to the phylum apicomplexan called Eimeria .
- Eimeria a protozoan parasite belonging to the phylum apicomplexan called Eimeria .
- Williams RB A compartmentalized model for the estimation of the cost of coccidiosis to the world's chicken production industry. Int J Parasitol. 1999; 29(8):1209-1229).
- antibiotics accumulated in animals due to the misuse of antibiotics are a serious problem as humans consume antibiotics through meat. Therefore, there is an urgent need to develop and research alternatives to existing anticoccidial agents that exhibit side effects such as the emergence of strains resistant to the drug and the problem of residual in the body.
- An example of the present application provides the use of coumaric acid and/or a salt thereof for preventing, improving, and/or treating coccidiosis.
- Another example of the present application provides a feed composition for preventing or improving coccidiosis, comprising coumaric acid and/or a salt thereof as an active ingredient.
- Another example of the present application provides a pharmaceutical composition for preventing or treating coccidiosis, comprising coumaric acid and/or a pharmaceutically acceptable salt thereof as an active ingredient.
- Another example of the present application provides the use of coumaric acid and/or a salt thereof for the preparation of a composition (eg, a feed composition, a pharmaceutical composition) for preventing, ameliorating, and/or treating coccidiosis.
- a composition eg, a feed composition, a pharmaceutical composition
- Another example of the present application includes the step of administering the composition (eg, the feed composition, the pharmaceutical composition, and/or the anti-antigen composition) to an animal other than a human, preventing, improving, and / or provide a method of treatment.
- the composition eg, the feed composition, the pharmaceutical composition, and/or the anti-antigen composition
- Another example of the present application is coumarin acid and / or salts thereof to the antigens of the genus Aimeria protozoa (for example, killing the protozoa of the genus Eimeria; and / or inhibition of cell penetration and / or proliferation of the protozoa of the genus Eimeria) It provides a purpose for use.
- Another example of the present application provides an antiprotozoal composition for protozoa of the genus Aimeria, comprising coumaric acid and/or a salt thereof as an active ingredient.
- Another example of the present application provides the use of coumaric acid and/or a salt thereof for use in the preparation of an antiprotozoal composition against the genus Eimeria protozoa.
- coumaric acid and/or a salt thereof is administered to an animal (eg, a subject in need of protozoan control, or an animal other than a human), preventing, improving, and/or It provides a method of treatment, or a method of controlling protozoa of the genus Aymeria.
- the control of protozoa refers to the antiprotozoal action inclusively, for example, it may mean the killing of the protozoa of the genus Aimeria, and/or inhibition of cell penetration and/or proliferation of the protozoa of the genus Eimeria. It is not limited.
- the coumarin acid may have a structure of Formula 1 below.
- a composition comprising coumaric acid and/or a salt thereof according to an embodiment may have excellent anti-coccidial activity and/or anti-protozoal activity against protozoa inducing coccidiosis.
- excellent anticoccidium efficacy is at least one selected from the group consisting of the following (1) to (5) (for example, one or more, two or more, three or more, four) above, or all 5 types):
- ACI Anticoccidial index
- control group is a negative control group (either no treatment group or water, and/or buffer treatment group) and/or a conventionally known anticoccidial agent (eg, diclazuril, gallic acid). ), and/or a positive control comprising salinomycin).
- negative control group either no treatment group or water, and/or buffer treatment group
- anticoccidial agent eg, diclazuril, gallic acid
- positive control comprising salinomycin
- composition according to an example is at least one selected from the group consisting of the following (1) to (6) (eg, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, or 6) all), and its properties may be superior to those of the control group:
- composition according to an embodiment has excellent acid resistance and/or heat resistance, so that it can be administered into the body to maintain excellent anticoccidial activity for a long period of time, has excellent in vivo stability, and has excellent anticoccidium activity even in environments of various temperatures and/or pH ranges. It can be maintained, can be applied to various products (eg, feed additives), and can have excellent storage stability.
- composition according to one embodiment is not absorbed into other tissues and organs (eg, blood, liver, kidney, and/or spleen, etc.) other than the intestine when administered in the body, so that the amount remaining in the body is small, so that the in vivo safety may be excellent.
- tissues and organs eg, blood, liver, kidney, and/or spleen, etc.
- the excellent effect of improving the weight gain may mean that the effect of being administered to an individual to increase the weight of the individual is excellent. It may be an object that has been
- composition according to one embodiment comprises a conventionally known anticoccidial agent (for example, a sulfa agent such as sulfaquinoxaline, sulfachloropyrazine, and sulfamethazine, a polyether ionophore antibiotic such as salinomycin and monensin sodium, Amphurolium, diclazuril, and/or toltrazuril) exhibits superior anticoccidium activity equal to or higher than that of coumarin acid and/or its salt, which is a substance that naturally participates in metabolism during the metabolic process as an active ingredient. It does not induce drug resistance and/or does not absorb into the body, so it is safe for long-term use.
- a conventionally known anticoccidial agent for example, a sulfa agent such as sulfaquinoxaline, sulfachloropyrazine, and sulfamethazine, a polyether ionophore antibiotic such as salinomycin and monen
- the composition according to one embodiment is resistant or does not remain in the body, so it can be used as a material for preventing, improving, and/or treating coccidium in laying hens as well as broilers.
- the composition according to an embodiment can significantly reduce the amount of oscitosis from an individual infected with anticoccidium-inducing protozoa, thereby reducing the rate of contamination and/or secondary infection of the barn.
- prevention refers to any action that suppresses or delays the onset of a disease by administration of the composition according to an embodiment
- treatment refers to an individual suspected and onset of a disease by administration of the composition according to an embodiment.
- improvement means any action that at least reduces a parameter related to a condition in which the disease is treated by administration of the composition according to an example, for example, at least the degree of the symptom can do.
- the disease may refer to coccidiosis.
- One aspect may provide a feed composition for preventing or improving coccidiosis, including coumaric acid and/or a salt thereof (coumaric acid, a salt of coumaric acid, or a combination thereof).
- the 'coumaric acid' is a kind of hydroxycinnamic acid, which is a hydroxy derivative of cinnamic acid, and in one example, the coumaric acid is p - coumaric acid, m -coumarin Acid ( m -coumaric acid), and o -coumaric acid ( o -coumaric acid) may be at least one selected from the group consisting of.
- the coumarin acid may be in a trans (trnas) type and/or a cis (cis) type.
- the p -coumaric acid may be trans- p -coumaric acid and/or cis- p - coumaric acid
- the m -coumaric acid is trans- p -coumaric acid.
- trans- m -coumaric acid trans- m -coumaric acid
- cis- m -coumaric acid cis- m -coumaric acid
- the o -coumaric acid is trans- o -coumaric acid (trans- o- ) coumaric acid) and/or cis- o - coumaric acid.
- the p -coumaric acid is '4-hydroxycinnamic acid', ' p -hydroxycinnamic acid ( p -Hydroxycinnamic acid), or 2-(4-hydroxyphenyl)acrylic acid (2-( 4-hydroxyphenyl)acrylic acid), and may have a molecular formula of C 9 H 8 O 3 .
- the p -coumaric acid may be represented by the following Formula 1 or Formula 2 or a mixture thereof (a compound represented by Formula 1 and a compound represented by Formula 2).
- the Cas number of the p -coumarin acid is Cas No. 501-98-4, Cas No. 7400-08-0, and/or Cas No. 4501-31-9.
- the m -coumaric acid is '3-hydroxycinnamic acid', ' m -hydroxycinnamic acid ( m -Hydroxycinnamic acid), or '3-(3-hydroxyphenyl)acrylic acid (3- (3-Hydroyphenyl)acrylic acid)', and may have a molecular formula of C 9 H 8 O 3 .
- the m -coumaric acid may be represented by the following Chemical Formula 3 or Chemical Formula 4, or a mixture thereof (a compound represented by Chemical Formula 3 and a compound represented by Chemical Formula 4).
- the Cas number of the m -coumarin acid is Cas No. 14755-02-3, Cas No. 25429-38-3, and/or Cas No. It can be 588-30-7.
- the o -coumaric acid may be named as '2-hydroxycinnamic acid' or '2-hydroxycinnamate', and has a molecular formula of C 9 H 8 O 3 can
- the o -coumaric acid may be represented by the following Chemical Formula 5 or Chemical Formula 6 or a mixture thereof (a compound represented by Chemical Formula 5 and a compound represented by Chemical Formula 6).
- the Cas number of the o -coumaric acid is Cas No. 614-60-8 and/or Cas No. 495-79-4.
- the coumaric acid and / or its salt (the salt of the coumarin acid) is obtained by extraction and separation from a natural product (eg, plant) and / or strain, or prepared by a conventional organic synthesis method, or a manufacturer in the art It can be obtained from, but is not limited thereto.
- salt of coumarin acid may mean a physiologically acceptable salt among salts that are substances in which cations and anions are combined by electrostatic attraction
- pharmaceutically acceptable salt is a pharmaceutical It may mean a salt in a form that can be used as, for example, a metal salt, a salt with an organic base, a salt with an inorganic acid, a salt with an organic acid, a salt with a basic or acidic amino acid, and the like.
- the metal salt may be an alkali metal salt (sodium salt, potassium salt, etc.), alkaline earth metal salt (calcium salt, magnesium salt, barium salt, etc.), aluminum salt, etc.;
- Salts with organic bases include triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N-dibenzylethylenediamine salts with, etc.
- salts with inorganic acids may be salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like;
- Salts with organic acids may be salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic
- coccidiosis refers to a protozoan coccidiosis (a protozoan capable of inducing coccidiosis, for example, a protozoa coccidiosis of the genus Eimeria) parasitizing in the cytoplasm of submucosal tissue in the epithelium of the digestive tract and destroying the epithelium. It is a protozoal disease that causes economic damage by lowering the weight gain rate and extending the shipping date due to soft stool, diarrhea and bloody stool in broiler farms, etc.
- Coccidiosis can be expressed not only in broilers, but also in birds, fish, reptiles and mammals, and specifically, the coccidiosis can be infected with cattle, rabbits, goats, dogs, cats, mice, experimental animals, rats, etc., especially chickens , can cause fatal damage to poultry such as ducks, geese, turkeys, quails and pheasants.
- the coccidiosis may include acute type coccidiosis, subacute type coccidiosis, and chronic type coccidiosis.
- the acute type coccidiosis shows bloody stool, loss of energy, and anemia within 48 hours after infection, and the infected individual may die, the subacute type coccidiosis may exhibit bloody diarrhea and/or anemia symptoms after infection, and the chronic type Coccidiosis may present with diarrhea followed by soft stools and/or weight loss for 1 to 2 days after infection.
- Oocysts (cysts, eggs) of the Coccidium protozoan species are infectious when they mature into sporulated oocysts at high humidity and temperature. If it is excreted, it is easily spread and the life cycle of the ostrich is repeated.
- the ocysts (cysts) of the Coccidium protozoan species are highly resistant to the external environment, and the cyst wall consists of two layers, inside and outside.
- the outer layer of the cyst wall is a gelatinous material that strongly resists physical external pressure, and the inner layer is rich in nuclear proteins, so it can strongly resist chemical stimuli, for example, disinfectants.
- the osspores of the Coccidium protozoan species may include four sporocysts, and the sporocysts may each include two sporozoites, and after infection in an animal in the form of an oste, the sporangia and sporozoite form
- the sporozoites that are released and proliferate in cells, and undergo sexual and/or asexual reproduction may form an ocyst and be excreted in feces.
- sporozoites may be used in the same sense as protozoa, and the sporozoites (protozoa) may cause lesions.
- the coccidiosis may be induced by a protozoa of the genus Eimeria sp.
- the protozoa of the genus Eimeria are Eimeria acervulina ( Eimeria acervulina ), Eimeria tenella ( Eimeria tenella : chicken cephalus), Eimeria maxima ( Eimeria maxima: maximacocephalus), Eimeria necatrix (Eimeria necatrix), Eimeria brunetti (Eimeria brunetti), Eimeria hagani ( Eimeria hagani : Eimeria mitis), Eimeria mitis : Eimeria praecox), Eimeria praecox ( Eimeria praecox ), Eimeria mivati ( Eimeria mivati : Mibathocephalus ), Eimeria aurati, Eimeria baueri ), Eimeria lepidosirenis , Eimeria leucisci , Eimeria aurati, E
- composition according to an example is induced by one or more (eg, one or more, two or more, three or more, or four or more) protozoa selected from the group consisting of protozoa of the genus Eimeria described in Table 1 below.
- the preventive, ameliorating, and/or therapeutic effects of coccidiosis may be excellent, and the protozoa of the genus Eimeria listed in Table 1 below may each induce coccidiosis in the animals listed in Table 1.
- Eimeria acervulina Chicken Gallus gallus domesticus 2 Eimeria tenella Chicken ( Gallus gallus domesticus ) 3 Eimeria maxima ( Eimeria maxima ) Chicken ( Gallus gallus domesticus ) 4 Eimeria necatrix Chicken ( Gallus gallus domesticus ) 5 Eimeria brunetti Chicken ( Gallus gallus domesticus ) 6 Eimeria hagani Chicken ( Gallus gallus domesticus ) 7 Eimeria mitis Chicken ( Gallus gallus domesticus ) 8 Eimeria praecox Chicken ( Gallus gallus domesticus ) 9 Eimeria mivati Chicken ( Gallus gallus domesticus ) 10 Aimeria Aurati ( Eimeria aurati ) Goldfish ( Carassius auratus ) 11 Eimeria baueri crucian carp ( Carassius carassius ) 12 Eimeria lepidosirenis South American lungfish ( Lepidosiren paradoxa ) 13 Eimeria leucisci barbel ( Barbus barbus boc
- Eimeria yemenensae rainbow agama (rock agama ( Agama yemenensis )) 19 Eimeria adenoeides turkey ( Meleagris gallopavo ) 20 Eimeria colchici pheasant (common pheasant ( Phasianus colchicus )) 21 Aymeria Culvata ( Eimeria curvata ) Gray-headed ground dove (ruddy ground dove ( Columbina talpacoti )), scaled dove ( Scardafella squammata )) 22 Eimeria dispersa turkey ( M.
- Eimeria phasiani pheasant P.
- Eimeria hircus 37 Eimeria arundeli Baby wombat (common wombat ( Vombatus ursinus )) 38 Eimeria bakuensis Sheep ( O. aries ) 39 Eimeria bovis Cattle ( B. taurus ) 40 Eimeria cameli camels (camels ( Camelus bactrianus , Camelus dromedarius )) 41 Eimeria caprina goat ( C. hircus ) 42 Eimeria caprovina ( Eimeria caprovina ) goat ( C. hircus ) 43 Eimeria christenseni goat ( C.
- Eimeria clethrionomyis Eimeria clethrionomyis
- red-backed vole Clethrionomys gapperi
- Eimeria coecicola rabbit Oryctolagus cuniculus
- Eimeria contorta mouse Mus musculus
- Eimeria couesii rice rat Oryzomys couesi
- Eimeria crandalis Eimeria crandallis Sheep ( O.
- Eimeria dammahensis Scimitar-homed oryx Oryx dammah ) 50 Eimeria dowleri eastern red bat ( Lasiurus borealis ) 51 Eimeria exigua rabbit ( Rabbit ( O. cuniculus )) 52 Eimeria falciformis ) mouse ( M. musculus ) 53 Eimeria farasanii mountain gazelle ( Gazella gazelle farasani ) 54 Eimeria ferrisi mouse ( M. musculus ) 55 Aimeria Flavescenes ( Eimeria flavescens ) rabbit ( Rabbit ( O.
- Eimeria larimerensis Uinta ground squirrel ( Spermophilus armatus ) 65 Aimeria makusaniensis ( Eimeria macusaniensis ) llamas ( Lama glama ), guanacos ( Lama guanicoe ), alpacas ( Vicugna pacos ), vicunas ( Vicugna vicugna )) 66 Aymeria Magna ( Eimeria magna ) rabbit ( Rabbit ( O. cuniculus )) 67 Eimeria marconii red-backed vole ( Clethrionomys gapperi ) 68 Eimeria media rabbit ( Rabbit ( O.
- Eimeria melanuri Glass dormouse Eliomys quercinus
- Eimeria myoxi Spectacled dormouse Eliomys quercinus
- Eimeria nagpurensis Eimeria nagpurensis
- Rabbit O. cuniculus
- 72 Eimeria nieschulzi brown rat ( R. norvegicus )
- Eimeria ninakohlyakimovae goat C. hircus
- Eimeria ovinoidalis Sheep O. aries )
- Eimeria pallida goat C.
- Eimeria phocae Sable Island harbor seals Phoca vitulina
- Eimeria pileata red-backed vole Clethrionomys gapperi
- Eimeria pipistrellus Eimeria pipistrellus
- Kuhl's pipistrelle Pipistrellus kuhlii
- Eimeria piriformis Eimeria piriformis
- Rabbit O.
- Eimeria prionotemni Red-necked wallaby (Bennett's wallaby ( Macropus rufogriseus ))
- Eimeria procyonis raccoon Procyon lotor )
- Eimeria punctate goat C. hircus
- Eimeria roobroucki rabbit Rabbit ( O. cuniculus )
- Eimeria saudiensis Arabian oryx Oryx leucoryx
- Eimeria sealanderi eastern red bat ( Lasiurus borealis )
- Eimeria separata mouse M.
- composition according to one embodiment may be excellent in preventing, improving, and/or treating coccidiosis induced by A. tenella, A. acebulina, and/or A. maxima.
- the prevention or improvement of coccidiosis means one or more (eg, one or more, two or more, three or more, or all four) selected from the group consisting of the following (1) to (4).
- one or more selected from the group consisting of the following (1) to (4) than the control may be decreased, inhibited, and / or increased:
- lesion score eg, cecal lesion score
- fecal oste excretion e.g., fecal oste excretion
- the lesion scoring method for determining the lesion score is described in Johnson JK & Reid WM (1970) (Joyce Johnson, W. Malcolm Reid, Anticoccidial drugs: Lesion scoring techniques in battery and floor-pen experiments with chickens, Experimental parasitology). , 1970), and the lesion score may be on a scale of 0 to 4.
- the lesion score may refer to a lesion score measured in the cecum, duodenum, and/or jejunum, and is calculated as the sum of respective lesion scores measured in each organ (caecum, duodenum, and/or jejunum).
- the amount of fecal oscosis excretion may be measured using a microscope or a counting chamber (eg, McMaster chamber) by collecting feces discharged from the subject.
- a microscope or a counting chamber eg, McMaster chamber
- the mortality rate may mean the mortality rate of the animal subject in which coccidiosis is induced, and the number of subjects who died due to causes other than coccidiosis may be excluded by performing a post-mortem autopsy.
- an individual with coccidiosis induced may lose weight more than an individual without coccidiosis, and the composition according to an embodiment may inhibit weight loss due to induction of coccidiosis.
- the anticoccidium composite index may be calculated by Equation 1 below, and the lesion score in Equation 1 may be calculated as described above.
- Composite anticoccidium index (ACI) (survival rate (%) after challenge inoculation) + (daily weight gain (%) compared to negative control group) - (lesion score x 10) - (fecal oscist discharge index)
- the aggressive inoculation may refer to administration of protozoa capable of inducing coccidiosis (eg, oral inoculation, etc.).
- the survival rate may be the survival rate measured at 5 to 10 days, 7 to 10 days, 8 to 10 days, 7 to 9 days, 7 to 8 days, or 7 days after challenge inoculation, by performing post-mortem autopsy
- the survival rate can be measured by excluding the number of individuals who died from causes other than coccidiosis.
- the amount of gain compared to the negative control may be a value calculated as a percentage calculated based on the value of the negative control (eg, a negative control uninfected with coccidium protozoa).
- Equation 1 The lesion score in Equation 1 is as described above.
- the fecal oscosis excretion index is calculated as a percentage based on the value of a negative control (eg, a negative control infected with protozoa), and if the calculated result is at a level of 0 to 1%, 0, 1 % or more and less than 26% may be 5, 26% or more to less than 51% is 10, 51% or more to less than 76% is 20, and 76% or more to 100% or less is 40.
- a negative control eg, a negative control infected with protozoa
- the coumaric acid and / or its salt is less than 1w / w%, less than 1w / w%, 10 -1 w / w% or less, 5 x 10 -2 w / w% or less, 2.5 x in the feed composition 10 -2 w/w% or less, 2 x 10 -2 w/w% or less, 1.25 x 10 -2 w/w% or less, 10 -2 w/w% or less, 9 x 10 -3 w/w% or less , 8 x 10 -3 w/w% or less, 6.25 x 10 -3 w/w% or less, 7 x 10 -3 w/w% or less, 6 x 10 -3 w/w% or less, 5 x10 -3 w/w% or less, 4 x 10 -3 w/w% or less, 10 -7 w/w% or more, 10 -6 w/w% or more, 10 -5 w/w%
- the coumaric acid and / or its salt is 1000ppm or less, 500ppm or less, 400ppm or less, 300ppm or less, 250ppm or less, 200ppm or less, 125ppm or less, 125ppm or less, 100ppm or less, 90ppm or less, 80ppm or less, 70ppm or less in the feed composition or less, 65ppm or less, 62.5ppm or less, 60ppm or less, 50ppm or less, 0.1ppm or more, 1ppm or more, 5ppm or more, 10ppm or more, 15ppm or more, 20ppm or more, 30ppm or more, 40ppm or more, 50ppm or more, 62.5ppm or more, 0.1 to 1000ppm , 0.1 to 500 ppm, 0.1 to 400 ppm, 0.1 to 300 ppm, 0.1 to 250 ppm, 0.1 to 200 ppm, 0.1 to 125 ppm, 0.1 to 100 ppm, 0.1 to 90 ppm or less
- feed may mean any natural or artificial diet, meal meal, etc. or a component of the meal meal for or suitable for the animal to eat, ingest, and digest.
- the feed composition according to an example may further include a concentrated feed and/or a special feed.
- the rich feed includes seed fruits including grains such as wheat, oats, and corn, bran, beans, fluid, sesame, linseed, coco palm, etc.
- Fish-Soluble (a by-product obtained from oil extraction), which is obtained by concentrating fresh liquids obtained from fish meal, fish waste, fish meal Animal feed such as dried whey, yeast, chlorella, and/or seaweed, etc. can
- the feed composition according to an example may refer to a feed in the form of a final ingested animal, a dietary supplement that can be formulated in the feed, and/or a feed additive.
- the dietary supplement is, for example, an agent-containing composition that provides a therapeutic agent or a digestive agent to an animal, and is not usually a source of caloric intake of a living body, that is, an energy source, but may refer to a composition that is ingested in addition to a normal animal feed.
- the feed additive is a material added to the feed for the purpose of various effects, such as nutrient supplementation and weight loss prevention, improvement of digestibility of fiber in feed, improvement of oil quality, prevention of reproductive disorders and improvement of fertility, prevention of high temperature stress in summer. . In one example, it may refer to a substance added for the purpose of preventing, improving, or treating coccidiosis.
- the feed composition may be a feed additive, and when the feed additive according to an example is formulated in a feed (eg, a compound feed and/or a simple feed that is finally consumed by an animal), Based on the total feed weight, 0.001% or more, 0.005% or more, 0.01% or more, 0.05% or more, 0.1% or more, 0.5% or more, 1% or less, 0.5% or less, 0.1% or less, 0.05% or less, 0.01% or less, 0.005% or less, 0.001 to 1%, 0.001 to 0.5%, 0.001 to 0.1%, 0.001 to 0.05%, 0.001 to 0.01%, 0.001 to 0.005%, 0.005 to 1%, 0.005 to 0.5%, 0.005 to 0.1%, 0.005 to 0.05%, 0.005 to 0.01%, 0.01 to 1%, 0.01 to 0.5%, 0.01 to 0.1%, 0.01 to 0.05%, 0.05 to 1%, 0.05 to 0.5%, 0.05 to 0.1%, 0.1 to
- Another aspect may provide a pharmaceutical composition for preventing or treating coccidiosis, including coumaric acid and/or a salt thereof, and for the above-described salt of coumaric acid and/or coumaric acid included in the pharmaceutical composition like a bar
- the pharmaceutical composition according to an embodiment may be used as a single agent, and may be prepared and used as a combination, further including a pharmaceutical composition known to have a recognized preventive or therapeutic effect on coccidiosis.
- a pharmaceutical unit dosage form may be formulated by adding a pharmaceutically acceptable carrier, excipient, or diluent.
- the pharmaceutical composition comprising a pharmaceutically acceptable carrier is a tablet, pill, powder, granule, capsule, suspension, internal solution, emulsion, syrup, sterile aqueous solution, non-aqueous solution, suspension, emulsion, It may have any one formulation selected from the group consisting of freeze-dried formulations and suppositories.
- the pharmaceutical composition may be in various oral or parenteral formulations.
- it can be prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. commonly used.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in one or more compounds, for example, starch, calcium carbonate, sucrose or lactose ( lactose), gelatin, etc.
- lubricants such as magnesium stearate, talc and the like may also be used.
- Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc.
- various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have.
- Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
- Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
- injectable esters such as ethyl oleate.
- As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like can be used.
- the pharmaceutical composition is in various forms, such as oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and injections of sterile injection solutions, according to conventional methods for each purpose of use. It can be formulated and used orally or administered through various routes including intravenous, intraperitoneal, subcutaneous, rectal, topical administration, and the like.
- the pharmaceutical composition may further include a carrier, excipient or diluent, and the like, and examples of suitable carriers, excipients or diluents that may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, Maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, amorphous cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- the pharmaceutical composition may further include a filler, an anti-aggregating agent, a lubricant, a wetting agent, a fragrance, an emulsifier, a preservative, and the like.
- the effective amount of the active ingredient (coumarin acid and/or its salt) in the pharmaceutical composition may vary depending on the age, sex, and weight of the patient (individual), and generally 0.0001 to 0.001 mg/kg of body weight kg, 0.0001 to 0.01 mg/kg, 0.0001 to 0.1 mg/kg, 0.0001 to 1 mg/kg, 0.0001 to 10 mg/kg, 0.0001 to 100 mg/kg, 0.0001 to 231 mg/kg, 0.0001 to 250 mg/kg, 0.0001 to 500 mg/kg kg, 0.0001 to 1000 mg/kg, 0.001 to 0.01 mg/kg, 0.001 to 0.1 mg/kg, 0.001 to 1 mg/kg, 0.001 to 10 mg/kg, 0.001 to 100 mg/kg, 0.001 to 231 mg/kg, 0.001 to 250 mg/kg kg, 0.001 to 500 mg/kg, 0.001 to 1000 mg/kg, 0.01 to 0.1 mg/kg, 0.01 to 1 mg/kg, 0.001 to 10 mg/kg,
- the dosage is not intended to limit the scope of the present invention in any way.
- the composition when administered intraperitoneally, it may be administered in an amount of 0.001 to 250 mg/kg or 0.001 to 231 mg/kg.
- the dosage of the pharmaceutical composition may vary depending on the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate, and severity of disease.
- the coumaric acid and / or its salt is less than 1w / w%, less than 1w / w%, 10 -1 w / w% or less, 5 x 10 -2 w / w% or less, 2.5 x in the pharmaceutical composition 10 -2 w/w% or less, 2 x 10 -2 w/w% or less, 1.25 x 10 -2 w/w% or less, 10 -2 w/w% or less, 9 x 10 -3 w/w% or less , 8 x 10 -3 w/w% or less, 6.25 x 10 -3 w/w% or less, 7 x 10 -3 w/w% or less, 6 x 10 -3 w/w% or less, 5 x10 -3 w/w% or less, 4 x 10 -3 w/w% or less, 10 -7 w/w% or more, 10 -6 w/w% or more, 10 -5 w/w%
- the coumaric acid and / or its salt is 1000ppm or less, 500ppm or less, 400ppm or less, 300ppm or less, 250ppm or less, 200ppm or less, 125ppm or less, 125ppm or less, 100ppm or less, 90ppm or less, 80ppm or less, 70ppm or less in the pharmaceutical composition or less, 65ppm or less, 60ppm or less, 62.5ppm or less, 50ppm or less, 0.1ppm or more, 1ppm or more, 5ppm or more, 10ppm or more, 15ppm or more, 20ppm or more, 30ppm or more, 40ppm or more, 50ppm or more, 62.5ppm or more, 0.1 to 1000ppm , 0.1 to 500 ppm, 0.1 to 400 ppm, 0.1 to 300 ppm, 0.1 to 250 ppm, 0.1 to 200 ppm, 0.1 to 125 ppm, 0.1 to 100 ppm, 0.1 to 90 ppm or less
- the pharmaceutical composition may be administered to a subject through various routes.
- the administration may mean providing a predetermined substance to an individual (patient) by any suitable method, and the administration route of the pharmaceutical composition is oral administration and/or through any general route as long as it can reach the target tissue. It may be administered parenterally.
- parenteral administration topical skin application, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and/or intrathoracic injection may be selected.
- the composition according to an embodiment may be administered using any device capable of delivering an active ingredient to a target cell.
- Another aspect may provide an antiprotozoal composition for the protozoa of the genus Eimeria, comprising coumaric acid and/or a salt thereof.
- Another aspect is a method of preventing, ameliorating, and/or treating coccidiosis, comprising administering coumaric acid and/or a salt thereof to an animal (eg, a subject in need of protozoan control, or an animal other than a human), or A method for controlling protozoa of the genus Aimeria is provided.
- control of protozoa refers to the antiprotozoal action inclusively, for example, it may mean the killing of the protozoa of the genus Aimeria, and/or inhibition of cell penetration and/or proliferation of the protozoa of the genus Eimeria. It is not limited.
- the coumaric acid, the salt of coumaric acid and/or the protozoa of the genus Aimeria are the same as described above.
- the excellent antiprotozoal activity (effect, efficacy) against the protozoa of the genus Eimeria may mean the characteristics of the following (1) and/or (2), for example, a control (negative control and/or positive control), and may exhibit the following characteristics (1) and/or (2):
- the coumaric acid, and / or a salt of coumarin acid may be included in the antiprotozoal composition in the concentration range as described above in the feed composition and / or pharmaceutical composition.
- the composition comprising the active ingredient in the above-mentioned concentration range may have superior anti-protozoal activity than when it is included in a range outside the concentration range.
- Another aspect includes administering the composition (eg, the feed composition, the feed additive, the pharmaceutical composition, and/or the anti-antigen composition) to an animal (eg, an animal other than a human) , a method for preventing, ameliorating, or treating coccidiosis.
- the method may further include identifying (selecting) an individual (patient) in need of prevention, improvement, or treatment of the coccidiosis.
- the composition and coccidiosis are as described above.
- the step of identifying the individual may include detecting an ossist of a protozoan capable of inducing coccidium in feces separated from the individual.
- the method of administering the composition, the route of administration, and/or the dosage are as described above.
- the composition may be administered in a pharmaceutically effective amount.
- a 'pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level refers to the type, severity, activity of the drug, and the drug Sensitivity to, administration time, administration route and excretion rate, duration of treatment, factors including concomitant drugs, and other factors well known in the medical field.
- the composition may be administered as an individual therapeutic agent or may be administered in combination with other anticoccidial agents, may be administered simultaneously, separately, or sequentially with a conventional therapeutic agent, and may be administered singly or multiple times. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.
- the subject to which the method for preventing, ameliorating, or treating coccidiosis is applied means an animal that has or can invent coccidiosis, and the animal includes humans, horses, cattle, mice, rats, dogs, cats, etc. birds, including mammals, poultry (eg, breeders, broilers, and/or laying hens, etc.), fish, amphibians, and/or reptiles.
- the animal includes humans, horses, cattle, mice, rats, dogs, cats, etc. birds, including mammals, poultry (eg, breeders, broilers, and/or laying hens, etc.), fish, amphibians, and/or reptiles.
- the animal to which the method for preventing, improving, or treating coccidiosis is applied is at least one selected from the group consisting of animals listed in Table 1 (eg, at least one, two or more, or three or more).
- animals listed in Table 1 can be, for example, humans, chickens, ducks, geese, turkeys, quails, pheasants, pigeons, parrots, cows, pigs, goats, sheep, horses, antelopes, oryx, monkeys, cats, dogs, mice, rats, rabbits, At least one selected from the group consisting of raccoon, squirrel, bat, guinea pig, camel, lima, alpaca, wombat, lizard, goldfish, crucian carp, tilapia, barbell, lungfish, and European chub (for example, one or more species, 2 more than one species, or three or more).
- the animal may be an animal other than a human.
- a composition comprising coumaric acid and/or a salt thereof according to an embodiment has an excellent effect of inhibiting cell infiltration of protozoa capable of inducing coccidiosis and/or of inhibiting proliferation of the protozoa in cells, and preventing, improving, and improving coccidiosis in vivo, and It has excellent therapeutic effect and can reduce secondary coccidiosis infection by remarkably reducing the amount of oocyst in feces.
- ACI anticoccidium composite index
- Example 1-1 Experimental facility and research design
- Korean feed A1-choi product Korean feed A1-choi product was used, and each material (salinomycin (Jeil Salino-60 product, Jeil Bio), VantiPEAL (Kemin, Cozante, main material: Gallic acid), p -coumaric acid was used in the feed. ( p -coumaric acid, CAS No. 501-98-4; sigma)) was added at the concentrations shown in Table 3 below and self-mixed. Antibiotics and supplements were not used in general feeds and formulated feeds, and no anticoccidial agents were added to each material. The broilers were fed ad libitum throughout the duration of the experiment.
- Coccidiosis induction was carried out by oral inoculation (challenge inoculation) of 10,000 ocysts per individual in 21-day-old broilers with oocysts of Aimeria tenella, which were more than 90% mature (sporulation).
- the feed formulation administered to the control group (negative control group or positive control group) and the test group and whether coccidiosis was induced by A. tenella were described in Table 3 below.
- Six 1-day-old broilers were bred in cages randomly placed for each control or test group, and after feeding the general feed for 14 days, the formulated feed prepared above was separately consumed for each control or test group.
- NC army process uninfected negative control
- PC general feed Infected negative control
- Coumarin acid intake group 1 Aymeria tenella infection + + p -coumaric acid (sigma) formulated feed containing 125ppm
- the anticoccidium efficacy for each test group designed in Example 1-2 was expressed as an anticoccidial index (ACI), and the anticoccidium composite index was calculated by Equation 2 below.
- ACI score is out of 200 points, and the higher the ACI score, the better the anticoccidial ability. It is judged to be excellent, and if the score is 160 or higher, it is judged that the anticoccidial effect is very good (Luis Miguel De Pablos et al., Anticoccidial activity of maslinic acid against infection with Eimeria tenella in chickens, Parasitol Res, 2010).
- Anticoccidium Composite Index (survival rate (%) after challenge inoculation) + (daily weight gain (RWG,%) compared to negative control group) - (lesion score x 10) - (fecal oscosis discharge index)
- the daily gain (ADG, g/d) and the daily gain (RWG, %) compared to the negative control group in each control and test group are shown in Table 4 below.
- Lesion scoring On the 9th day after challenge inoculation, 4 broilers per cage were necropsied and the intestines were incised open. A score was scored for each coccidial lesion in the cecal region of broilers. The lesion scoring method was performed with reference to Johnson JK & Reid WM (1970) literature (Joyce Johnson, W. Malcolm Reid, Anticoccidial drugs: Lesion scoring techniques in battery and floor-pen experiments with chickens, Experimental parasitology, 1970). Lesion score has a scale of 0-4, with 0 being normal cecum, 1 being mild infection, 2 being moderate infection, 3 being severe infection, and 4 being very severe infection. It applies to cases that show symptoms or cause death. The cecal lesion scores measured in each control group and test group are shown in Table 4 below. The measured cecal lesion score was multiplied by 10 to obtain a lesion index, which was used to calculate the anticoccidium composite index.
- Fecal oscary discharge All feces from the 6th to 9th days of challenge inoculation were collected by cage and mixed evenly, and then randomly sampled 3 times, 1g each. After floating the ocysts in 1 g of feces using brine, the oste emissions were measured using a McMaster chamber, and the results are shown in Table 4 below.
- the amount of osteous discharge for each group was divided by that of the negative infected control group and multiplied by 100 to calculate the amount of osteous discharge (%) compared to the negative infected control group.
- the amount of oscitosis output is 0 to less than 1%, 5 for 1% to less than 26%, 10 for 26% to less than 51%, 20, 76 for more than 51% and less than 76%.
- % or more to 100% or less was 40 to calculate the oscit emission index, and this was used to calculate the anticoccidium composite index.
- Group control test group Compounds NC PC Salinomycin VantiPEARL p -coumaric acid conc (ppm) 60 125 125 broiler chicken 18 18 18 18 18 ADG after attack (g/d) 55 37 45 49 52 RWG(%) 100 67.3 81.8 89.1 94.5 Survival rate (%) 100 100 100 100 100 appendix lesion score 0 3.37 2.27 2.17 2.5 appendix lesion index - 33.7 22.7 21.7 25 Osist Emissions (Oocyst/chicken) 0 1.3x10 8 6.3x10 7 8x10 7 5.7x10 7 Oocyst index 0 40 10 20 10 ACI 200 94 149 147 160
- the negative control group (PC) infected with Aymeria tenella developed coccidiosis compared to the non-infected negative control group (NC), resulting in a decrease in weight gain, and an increase in lesion score and ocyst (egg) discharge.
- the salinomycin-administered group which was used as the anticoccidial control group, increased the body weight and decreased the lesion score and ocyst discharge compared to the infected negative control group (PC).
- the VantiPEARL-administered group which is a control group for natural anticoccidium, also increased the weight gain and decreased egg discharge and lesion index compared to the PC group.
- the p -coumaric acid administration group increased the amount of weight gain compared to the PC group, and decreased the lesion score and ocyst discharge.
- the p -coumaric acid administered group 125ppm scored 160 points, and the anticoccidium efficacy was superior to the positive control groups, Salinomycin (149 points) and VantiPEAL (147 points).
- Example 3 Aimeria of coumarin acid ( Eimeria ) Inhibitory effect of cell penetration and proliferation against protozoa
- a certain amount of each Aymeria tenella and Aymeria acebulina is placed in a tube containing glass beads and pulverized, and then the percoll density gradient is used to remove the crushed cell wall and other debris. to purify internal sporocysts, and wash with PBS solution.
- the sporangia of A. acebulina and A. tenella were treated with a reagent containing sodium taurocholic acid (Sigma aldrich, USA) and trypsin (trypsin, Gibco, USA), respectively. After incubation, it was washed once with a PBS solution, and protozoa was obtained.
- Example 3-2 Inhibitory effect of protozoan cell infiltration and intracellular protozoan proliferation by coumaric acid treatment
- Protozoa of A. tenella and A. acebulina were obtained by the method of Example 3-1. 2x10 5 sporozoites per well were added to the wells lined with MDBK cells (purchased from ATCC) as a monolayer and each Material ( p -coumaric acid; sigma, CAS No. 501-98-4, and anticoccidial gallic acid; sigma, CAS No. 149-91-7, salinomycin; CAS No. sigma, 53003-10-4, Diclazuril; sigma, CAS No.
- DNA is extracted from the cells using a DNA extract kit (Intron Biotechnology), and E.tenella ITS-1 (Internal transcribed spacer-1) gene or E. acervulina ACE gene Real-time PCR was performed using specific primers. The sequences of the primers used are shown in Table 5 below.
- a protozoan of A. tenella was obtained similarly to the method of Example 3-1. 2x10 5 sporozoites per well were added to wells lined with MDBK cells (purchased from ATCC) as a monolayer and incubated for 24 hours at a temperature of 40° C. washed. Each Materials ( p -coumaric acid, gallic acid, an anticoccidial agent, salinomycin: 10 ppm and diclazuril: 1 ppm) were treated with the cells, and further cultured at a temperature of 40° C. for 24 hours.
- a negative control is MDBK cells infected with protozoa
- a positive control refers to a group incubated with a solution of salinomycin, gallic acid, or diclazuril and protozoa. After removing the cells and proliferating protozoa through pipetting, DNA was extracted from the cells using a DNA extract kit (Intron Biotechnology), and PCR was performed using E.tenella ITS-1 specific primers. The primer sequences used are shown in Table 5 above.
- diclazuril is effective in inhibiting proliferation of protozoa in cells
- gallic acid is effective only in infiltrating protozoa cells
- coumaric acid is infiltrating Aymeria tenella protozoa and intracellular protozoa. All of the proliferation (propagation) was inhibited, and the degree was superior to that of the positive control group.
- the cell penetration inhibitory efficacy against Eimeria acebulina in the coumarin acid-treated group was superior to all the positive controls (diclazuril, gallic acid, and salinomycin).
- Example 4-1 Aimeria ( Eimeria ) direct killing effect on protozoa
- the inner sporocysts are purified using the Percoll density gradient and , washed with PBS solution.
- A. tenella sporangia was treated with a reagent containing sodium taurocholic acid (sigma aldirich, USA) and trypsin (Trypsin, Ginco, USA), respectively, and incubated with PBS After washing once with the solution, protozoa were obtained.
- m -coumaric acid showed a direct killing effect on the protozoa of the genus Eimeria significantly superior to Caffeic acid and Ferulic acid.
- Example 3-2 0.1% DMSO, p -coumaric acid (sigma, CAS No. 501-98-4), m -coumaric acid (sigma, 14755-02-3), and o -coumaric acid in a manner similar to Example 3-2 (sigma, 614-60-8) was treated at a concentration of 10 ppm, respectively, to measure cell invasion inhibition against A. tenella protozoa, and the results are shown in Table 9.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Birds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Detergent Compositions (AREA)
Abstract
Description
species | 호스트(host) 동물 | |
1 | 아이메리아 아세불리나 (Eimeria acervulina) | 닭 (Gallus gallus domesticus) |
2 | 아이메리아 테넬라(Eimeria tenella) | 닭 (Gallus gallus domesticus) |
3 | 아이메리아 맥시마(Eimeria maxima) | 닭 (Gallus gallus domesticus) |
4 | 아이메리아 네카트릭스 (Eimeria necatrix) | 닭 (Gallus gallus domesticus) |
5 | 아이메리아 브루네티 (Eimeria brunetti) | 닭 (Gallus gallus domesticus) |
6 | 아이메리아 하가니(Eimeria hagani) | 닭 (Gallus gallus domesticus) |
7 | 아이메리아 미티스(Eimeria mitis) | 닭 (Gallus gallus domesticus) |
8 | 아이메리아 프래콕스 (Eimeria praecox) | 닭 (Gallus gallus domesticus) |
9 | 아이메리아 미바티(Eimeria mivati) | 닭 (Gallus gallus domesticus) |
10 | 아이메리아 아우라티 (Eimeria aurati) |
금붕어 (goldfish (Carassius auratus)) |
11 | 아이메리아 바루에리(Eimeria baueri) | 붕어 (crucian carp (Carassius carassius)) |
12 | 아이메리아 레피도시레니스(Eimeria lepidosirenis) | 남아메리카폐어(South American lungfish (Lepidosiren paradoxa)) |
13 | 아이메리아 류시스시(Eimeria leucisci) | 바벨 (common barbel (Barbus barbus bocagei)) |
14 | 아이메리아 루틸리 (Eimeria rutile) |
유럽산 처브 (European chub (Leuciscus cephalus cabeda)), 이베리아 코 잉어 (Iberian nase (Chondrostoma polylepis polylepis)) |
15 | 아이메리아 바나시 (Eimeria vanasi) |
블루 틸라피아 (blue tilapia (Oreochromis aureus)) |
16 | 아이메리아 앰피스배니아룸(Eimeria amphisbaeniarum) | 웜도마뱀 (Mann's worm lizard (Amphisbaena manni)) |
17 | 아이메리아 윗처리(Eimeria witchery) | 웜도마뱀 (Mann's worm lizard (A. manni)) |
18 | 아이메리아 예메낸새(Eimeria yemenensae) | 무지개 아가마 (rock agama (Agama yemenensis)) |
19 | 아이메리아 아데노에이데스(Eimeria adenoeides) | 칠면조 (turkey (Meleagris gallopavo)) |
20 | 아이메리아 콜치씨(Eimeria colchici) | 꿩 (common pheasant (Phasianus colchicus)) |
21 | 아이메리아 컬바타 (Eimeria curvata) |
회색머리땅비둘기 (ruddy ground dove (Columbina talpacoti)), 비늘작은비둘기 (scaled dove (Scardafella squammata)) |
22 | 아이메리아 디스펄사(Eimeria dispersa) | 칠면조 (turkey (M. gallopavo)), 메추라기 (bobwhite quail (Colinus virginianus)) |
23 | 아이메리아 두오데나리스(Eimeria duodenalis) | 꿩 (common pheasant (Phasianus colchicus)) |
24 | 아이메리아 프라터큘래(Eimeria fraterculae) | 아틀란틱 퍼핀 (Atlantic puffin (Fratercula arctica)) |
25 | 아이메리아 갈로파보니스(Eimeria gallopavonis) | 칠면조 (turkey (M. gallopavo)) |
26 | 아이메리아 이노쿠아(Eimeria innocua) | 칠면조 (turkey (M. gallopavo)) |
27 | 아이메리아 멜레그리디스(Eimeria meleagridis) | 칠면조 (turkey (M. gallopavo)) |
28 | 아이메리아 멜레그리미티스(Eimeria meleagrimitis) | 칠면조 (turkey (M. gallopavo)) |
29 | 아이메리아 파시아니(Eimeria phasiani) | 꿩 (pheasant (P. colchicus)) |
30 | 아이메리아 프로쎄라(Eimeria procera) | 유럽반시 (grey partridges (Perdix perdix)) |
31 | 아이메리아 펄퓨어이쎄팔리(Eimeria purpureicephali) | 보석앵무 (red-capped parrot (Purpureicephalus spurius)) |
32 | 아이메리아 아사타(Eimeria ahsata) | 염소 (goat (Capra hircus)), 양 (sheep (Ovis aries)) |
33 | 아이메리아 알바멘시스(Eimeria alabamensis) | 소 (cattle (Bos taurus)) |
34 | 아이메리아 알리제비(Eimeria alijevi) | 염소 (goat (C. hircus)) |
35 | 아이메리아 아스퍼로니카(Eimeria aspheronica) | 염소 (goat (C. hircus)) |
36 | 아이메리아 아를로인지(Eimeria arloingi) | 염소 (goat (C. hircus)) |
37 | 아이메리아 아룬델리(Eimeria arundeli) | 애기 웜뱃 (common wombat (Vombatus ursinus)) |
38 | 아이메리아 바쿠엔시스(Eimeria bakuensis) | 양 (sheep (O. aries)) |
39 | 아이메리아 보비스(Eimeria bovis) | 소 (cattle (B. taurus)) |
40 | 아이메리아 카멜리(Eimeria cameli) | 낙타 (camels (Camelus bactrianus, Camelus dromedarius)) |
41 | 아이메리아 카프리나(Eimeria caprina) | 염소 (goat (C. hircus)) |
42 | 아이메리아 카프로비나(Eimeria caprovina) | 염소 (goat (C. hircus)) |
43 | 아이메리아 크리스텐세니(Eimeria christenseni) | 염소 (goat (C. hircus)) |
44 | 아이메리아 클레트리오노미스(Eimeria clethrionomyis) | 대륙밭쥐속 (red-backed vole (Clethrionomys gapperi)) |
45 | 아이메리아 코에씨콜라(Eimeria coecicola) | 토끼 (rabbit (Oryctolagus cuniculus)) |
46 | 아이메리아 콘토르타(Eimeria contorta) | 마우스 (mouse (Mus musculus)) |
47 | 아이메리아 코우에씨(Eimeria couesii) | 쌀쥐 (rice rat (Oryzomys couesi)) |
48 | 아이메리아 크랜달리스(Eimeria crandallis) | 양 (sheep (O. aries)) |
49 | 아이메리아 다마헨시스(Eimeria dammahensis) | 긴칼뿔오릭스 (scimitar-homed oryx (Oryx dammah)) |
50 | 아이메리아 도우레리(Eimeria dowleri) | 붉은나무박쥐(eastern red bat (Lasiurus borealis)) |
51 | 아이메리아 엑시구아(Eimeria exigua) | 토끼 (rabbit (O. cuniculus)) |
52 | 아이메리아 팔씨포르미스(Eimeria falciformis) | 마우스 (mouse (M. musculus)) |
53 | 아이메리아 파라사니(Eimeria farasanii) | 마운틴 가젤 (mountain gazelle (Gazella gazelle farasani)) |
54 | 아이메리아 페리시(Eimeria ferrisi) | 마우스 (mouse (M. musculus)) |
55 | 아이메리아 플라베씬스 (Eimeria flavescens) |
토끼 (rabbit (O. cuniculus)) |
56 | 아이메리아 갈라티(Eimeria gallatii) | 대륙밭쥐속(red-backed vole (Clethrionomys gapperi)) |
57 | 아이메리아 그래눌로사(Eimeria granulosa) | 염소 (goat (C. hircus)) |
58 | 아이메리아 히르씨(Eimeria hirci) | 염소 (goat (C. hircus)) |
59 | 아이메리아 인테스트이날리스(Eimeria intestinalis) | 토끼 (rabbit (O. cuniculus)) |
60 | 아이메리아 이레시두아(Eimeria irresidua) | 토끼 (rabbit (O. cuniculus)) |
61 | 아이메리아 인트리카타(Eimeria intricata) | 염소 (goat (C. hircus)) |
62 | 아이메리아 졸치제비(Eimeria jolchijevi) | 염소 (goat (C. hircus)) |
63 | 아이메리아 크링즈마니(Eimeria krijgsmanni) | 마우스 (mouse (M. musculus)) |
64 | 아이메리아 래리머렌시스(Eimeria larimerensis) | 유인타땅다람쥐 (Uinta ground squirrel (Spermophilus armatus)) |
65 | 아이메리아 마쿠사니엔시스 (Eimeria macusaniensis) |
라마 (llamas (Lama glama)), 구아나코 (guanacos (Lama guanicoe)), 알파카 (alpacas (Vicugna pacos)), 비쿠냐 (vicunas (Vicugna vicugna)) |
66 | 아이메리아 마그나 (Eimeria magna) |
토끼 (rabbit (O. cuniculus)) |
67 | 아이메리아 마르코니(Eimeria marconii) | 대륙밭쥐속 (red-backed vole (Clethrionomys gapperi)) |
68 | 아이메리아 메디아(Eimeria media) | 토끼 (rabbit (O. cuniculus)) |
69 | 아이메리아 멜라누리(Eimeria melanuri) | 안경겨울잠쥐(garden dormouse (Eliomys quercinus)) |
70 | 아이메리아 미옥시(Eimeria myoxi) | 안경겨울잠쥐(garden dormouse (Eliomys quercinus)) |
71 | 아이메리아 나그푸렌시스(Eimeria nagpurensis) | 토끼 (rabbit (O. cuniculus)) |
72 | 아이메리아 니에스쿨지(Eimeria nieschulzi) | 시궁쥐 (brown rat (R. norvegicus)) |
73 | 아이메리아 니나콜야키모배(Eimeria ninakohlyakimovae) | 염소 (goat (C. hircus)) |
74 | 아이메리아 오비노달리스(Eimeria ovinoidalis) | 양 (sheep (O. aries)) |
75 | 아이메리아 팔리다(Eimeria pallida) | 염소 (goat (C. hircus)) |
76 | 아이메리아 팔루스트리스(Eimeria palustris) | 쌀쥐 (marsh rice rat (Oryzomys palustris)) |
77 | 아이메리아 파필라타(Eimeria papillata) | 마우스 (mouse (M. musculus)) |
78 | 아이메리아 퍼르포란스(Eimeria perforans) | 토끼 (rabbit (O. cuniculus)) |
79 | 아이메리아 포캐(Eimeria phocae) | 사블섬 잔점박이물범 (Sable Island harbour seals (Phoca vitulina)) |
80 | 아이메리아 필레타(Eimeria pileata) | 대륙밭쥐속 (red-backed vole (Clethrionomys gapperi)) |
81 | 아이메리아 피피스트렐루스(Eimeria pipistrellus) | 쿨집박쥐 (Kuhl's pipistrelle (Pipistrellus kuhlii)) |
82 | 아이메리아 피리포르미스(Eimeria piriformis) | 토끼 (rabbit (O. cuniculus)) |
83 | 아이메리아 프리오노템니(Eimeria prionotemni) | 붉은목왈라비 (Bennett's wallaby (Macropus rufogriseus)) |
84 | 아이메리아 프로시오니스(Eimeria procyonis) | 라쿤(raccoon (Procyon lotor)) |
85 | 아이메리아 펀크타타(Eimeria punctate) | 염소 (goat (C. hircus)) |
86 | 아이메리아 루브루키(Eimeria roobroucki) | 토끼 (rabbit (O. cuniculus)) |
87 | 아이메리아 사우디엔시스(Eimeria saudiensis) | 아라비아 영양 (Arabian oryx (Oryx leucoryx)) |
88 | 아이메리아 시란데리(Eimeria sealanderi) | 붉은나무박쥐 (eastern red bat (Lasiurus borealis)) |
89 | 아이메리아 세파라타(Eimeria separata) | 마우스 (mouse (M. musculus)),랫트 (rat (Rattus rattus)) |
90 | 아이메리아 스티에대(Eimeria stiedae) | 토끼 (rabbit (O. cuniculus)) |
91 | 아이메리아 우르시니(Eimeria ursini) | 남방털코웜뱃 (southern hairy nosed wombat (Lasiorhinus latifrons)) |
92 | 아이메리아 베르미포르미스(Eimeria vermiformis) | 마우스 (mouse (M. musculus)) |
93 | 아이메리아 웨이브리드젠시스(Eimeria weybridgensis) | 양 (sheep (O. aries)) |
94 | 아이메리아 우바티(Eimeria wobati) | 남장털코웜뱃 (southern hairy-nosed wombat (L. latifrons)) |
95 | 아이메리아 주에르니(Eimeria zuernii) | 소 (cattle (B. taurus)) |
카테고리 | 실험변수 |
사육타입 | 케이지 |
육계 입식 일령 | 1일령 |
총 실험기간 | 30일 |
성별 | 암컷 |
케이지 별 육계 수 | 6마리 |
처리구 별 반복 수 | 3반복 |
처리구 수 | 5가지 |
육계의 총 수 | 90수 |
공격접종 원충의 종류 | 아이메리아 테넬라 |
공격접종 오시스트 수 | 10,000 오시스트 구강접종/마리 |
군 | 처리 |
비감염된 음성 대조군 (NC) | 일반 사료 |
감염된 음성 대조군(PC) | 아이메리아 테넬라 감염 + 일반 사료 |
양성 대조군 1 | 아이메리아 테넬라 감염 + 살리노마이신 60ppm 포함 배합사료 |
양성 대조군 2 | 아이메리아 테넬라 감염 + VantiPEAL(Kemin) 125ppm 포함 배합사료 |
쿠마린산 섭취군 1 | 아이메리아 테넬라 감염 + + p-coumaric acid(sigma) 125ppm 포함 배합사료 |
Group | 대조군 | 시험군 | |||
Compounds | NC | PC | Salinomycin | VantiPEARL | p-coumaric acid |
conc(ppm) | 60 | 125 | 125 | ||
육계두수 | 18 | 18 | 18 | 18 | 18 |
공격접 후ADG(g/d) | 55 | 37 | 45 | 49 | 52 |
RWG(%) | 100 | 67.3 | 81.8 | 89.1 | 94.5 |
생존율(%) | 100 | 100 | 100 | 100 | 100 |
맹장병변 스코어 | 0 | 3.37 | 2.27 | 2.17 | 2.5 |
맹장병변 지수 | - | 33.7 | 22.7 | 21.7 | 25 |
오시스트 배출량 (Oocyst/chicken) |
0 | 1.3x108 | 6.3x107 | 8x107 | 5.7x107 |
Oocyst index | 0 | 40 | 10 | 20 | 10 |
ACI | 200 | 94 | 149 | 147 | 160 |
프라이머 | 염기서열(5'->3') | 서열번호 | |
E.tenella ITS-1 | Forward | TGGAGGGGATTATGAGAGGA | 서열번호 1 |
Reverse | CAAGCAGCATGTAACGGAGA | 서열번호 2 | |
E.acervulina ACE | Forward | GCAGTCCGATGAAAGGTATTTG | 서열번호 3 |
Reverse | GAAGCGAAATGTTAGGCCATCT | 서열번호 4 |
sample | Invasion inhibition% | Propagation inhibition % |
NC | 0.0 | 0.0 |
Diclazuril | 6.3 | 52.9 |
Salinomycin | 56.4 | 34.8 |
Gallic acid | 90.1 | 0.0 |
p-coumaric acid | 54.3 | 43.9 |
sample | Invasion inhibition% |
NC | 0.0 |
Diclazuril | 42.7 |
Salinomycin | 59.4 |
Gallic acid | 60.6 |
p-coumaric acid | 82.6 |
sample | Dose (ppm) |
Killed sporozoites % |
Cell only | 0 | |
0.1% DMSO | 0 | |
m-coumaric acid | 10 | 10.7 |
Caffeic acid | 10 | 0 |
Ferulic acid | 10 | 0 |
sample | Dose (ppm) |
Invasion inhibition% |
Cell only | 0 | |
0.1% DMSO | 0 | |
p-coumaric acid | 10 | 7.98 |
m-coumaric acid | 10 | 29.78 |
o-coumaric acid | 10 | 39.57 |
Claims (9)
- 쿠마린산(coumaric acid) 또는 이의 염을 유효성분으로 포함하는, 콕시듐증 예방, 또는 개선용 사료 조성물.
- 제1항에 있어서, 상기 콕시듐증은 아이메리아 속(Eimeria sp.) 원충에 의해 유도되는 것인, 사료 조성물.
- 제1항에 있어서, 상기 쿠마린산은 p-쿠마린산(p-coumaric acid), m-쿠마린산(m-coumaric acid), 및 o-쿠마린산(o-coumaric acid)로 이루어진 군에서 선택된 1종 이상인, 사료 조성물.
- 제1항에 있어서, 상기 콕시듐증 예방 또는 개선은 하기 (1) 내지 (4)로 이루어지는 군에서 선택된 1종 이상인, 사료 조성물:(1) 병변 스코어, 분변 오시스트 배출양, 및 폐사율로 이루어지는 군에서 선택된 1종 이상이 감소;(2) 콕시듐증에 의한 체중 감소의 억제;(3) 항콕시듐 종합지수(Anticoccidial index; ACI)가 증가; 및(4) 아이메리아 속 원충의 세포 침투, 세포 내 상기 원충의 증식, 또는 이들 모두를 감소.
- 제1항에 있어서, 상기 사료 조성물은 상기 유효성분을 전체 중량 기준으로 1%(w/w) 이하의 농도로 포함하는 사료인, 사료 조성물.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 사료 조성물은 사료 첨가제인, 사료 조성물.
- 쿠마린산(Coumaric acid) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는, 콕시듐증 예방, 또는 치료용 약학 조성물.
- 쿠마린산(Coumaric acid) 또는 이의 염을 유효성분으로 포함하는, 아이메리아 속 원충에 대한 항원충용 조성물.
- 제1항 내지 제5항 중 어느 한 항에 따른 사료 조성물, 제7항에 따른 약학 조성물, 및 제8항에 따른 항원충용 조성물로 이루어지는 군에서 선택된 조성물을 인간을 제외한 동물에 투여하는 단계를 포함하는, 콕시듐증 예방, 개선, 또는 치료 방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22763629.7A EP4302608A1 (en) | 2021-03-05 | 2022-03-04 | Anticoccidial composition comprising coumaric acid and use thereof |
JP2023519072A JP2023545650A (ja) | 2021-03-05 | 2022-03-04 | クマル酸を含む抗コクシジウム用組成物およびその用途 |
CN202280006974.3A CN116528847A (zh) | 2021-03-05 | 2022-03-04 | 包含香豆酸的抗球虫组合物及其用途 |
BR112023007086A BR112023007086A2 (pt) | 2021-03-05 | 2022-03-04 | Composição anticoccidiana compreendendo ácido cumárico e uso da mesma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0029733 | 2021-03-05 | ||
KR1020210029733A KR20220125628A (ko) | 2021-03-05 | 2021-03-05 | 쿠마린산을 포함하는 항콕시듐용 조성물 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022186648A1 true WO2022186648A1 (ko) | 2022-09-09 |
Family
ID=83154230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/003072 WO2022186648A1 (ko) | 2021-03-05 | 2022-03-04 | 쿠마린산을 포함하는 항콕시듐용 조성물 및 이의 용도 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4302608A1 (ko) |
JP (1) | JP2023545650A (ko) |
KR (1) | KR20220125628A (ko) |
CN (1) | CN116528847A (ko) |
BR (1) | BR112023007086A2 (ko) |
WO (1) | WO2022186648A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080160000A1 (en) | 2006-10-31 | 2008-07-03 | Marubeni Nisshin Feed Co., Ltd. | Coccidiosis and clostridial disease prophylactic and/or therapeutic feed for coccidiosis and clostridial disease |
KR20160145328A (ko) * | 2015-06-10 | 2016-12-20 | 주식회사 케어사이드 | 닭 콕시듐 치료 또는 예방용 약학 조성물 |
KR20180083818A (ko) * | 2017-01-12 | 2018-07-23 | 차장옥 | 콕시듐증 예방 또는 치료용 조성물, 이의 제조방법 및 이의 이용 |
WO2020152673A1 (en) * | 2019-01-21 | 2020-07-30 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Anti-apicomplexan compositions |
WO2021016141A1 (en) * | 2019-07-20 | 2021-01-28 | Academia Sinica | Anti-coccidial phytogenic formulations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2291485T3 (es) | 2001-07-27 | 2008-03-01 | Alltech, Inc. | Metodos y composiciones para el control de coccidiosis. |
-
2021
- 2021-03-05 KR KR1020210029733A patent/KR20220125628A/ko not_active Application Discontinuation
-
2022
- 2022-03-04 BR BR112023007086A patent/BR112023007086A2/pt unknown
- 2022-03-04 CN CN202280006974.3A patent/CN116528847A/zh active Pending
- 2022-03-04 JP JP2023519072A patent/JP2023545650A/ja active Pending
- 2022-03-04 EP EP22763629.7A patent/EP4302608A1/en active Pending
- 2022-03-04 WO PCT/KR2022/003072 patent/WO2022186648A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080160000A1 (en) | 2006-10-31 | 2008-07-03 | Marubeni Nisshin Feed Co., Ltd. | Coccidiosis and clostridial disease prophylactic and/or therapeutic feed for coccidiosis and clostridial disease |
KR20160145328A (ko) * | 2015-06-10 | 2016-12-20 | 주식회사 케어사이드 | 닭 콕시듐 치료 또는 예방용 약학 조성물 |
KR20180083818A (ko) * | 2017-01-12 | 2018-07-23 | 차장옥 | 콕시듐증 예방 또는 치료용 조성물, 이의 제조방법 및 이의 이용 |
WO2020152673A1 (en) * | 2019-01-21 | 2020-07-30 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Anti-apicomplexan compositions |
WO2021016141A1 (en) * | 2019-07-20 | 2021-01-28 | Academia Sinica | Anti-coccidial phytogenic formulations |
Non-Patent Citations (7)
Title |
---|
ABBAS ASGHAR, IQBAL ZAFAR, ABBAS RAO ZAHID, KHAN MUHAMMAD KASIB, KHAN JUNAID ALI, SINDHU ZIA UD DIN, MAHMOOD MUHAMMAD SHAHID, SALE: "In vivo anticoccidial effects of Beta vulgaris (sugar beet) in broiler chickens", MICROBIAL PATHOGENESIS, ACADEMIC PRESS LIMITED, NEW YORK, NY., US, vol. 111, 1 October 2017 (2017-10-01), US , pages 139 - 144, XP055962971, ISSN: 0882-4010, DOI: 10.1016/j.micpath.2017.07.052 * |
CAS , no. 101831-37-2 |
CAS , no. 25429-38-3 |
CAS, no. 14755-02-3 |
JOYCE JOHNSONW.MALCOLM REID: "Anticoccidial drugs: Lesion scoring techniques in battery and floor-pen experiments with chickens", EXPERIMENTAL PARASITOLOGY, 1970 |
LUIS MIGUEL DE PABLOS ET AL.: "Anticoccidial activity of maslinic acid against infection with Eimeria tenella in chickens", PARASITOL RES, 2010 |
WILLIAMS RB: "A compartmentalised model for the estimation of the cost of coccidiosis to the world's chicken production industry", INT J PARASITOL, vol. 29, no. 8, 1999, pages 1209 - 1229 |
Also Published As
Publication number | Publication date |
---|---|
CN116528847A (zh) | 2023-08-01 |
BR112023007086A2 (pt) | 2023-10-10 |
KR20220125628A (ko) | 2022-09-14 |
JP2023545650A (ja) | 2023-10-31 |
EP4302608A1 (en) | 2024-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018048056A1 (ko) | 담팔수 추출물 또는 이의 분획물을 유효 성분으로 포함하는 알파 계열 허피스 바이러스 감염증의 예방 및 치료용 약제학적 조성물 | |
US5135746A (en) | Control of protozoal disease | |
US10568897B2 (en) | Bidens pilosa and polyacetylenic compounds for prevention and treatment of coccidiosis | |
WO2022065914A1 (ko) | 은행잎을 포함하는 항콕시듐용 조성물 및 이의 용도 | |
US20210329946A1 (en) | Berberine alkaloid formulations in the prevention and/or treatment of infectious disease | |
WO2022186648A1 (ko) | 쿠마린산을 포함하는 항콕시듐용 조성물 및 이의 용도 | |
Hu et al. | Effect of anticoccidials and antibiotics on the control of blackhead disease in broiler breeder pullets | |
US6569843B1 (en) | Steroidal sapogenins for the control of coccidiosis in animals | |
WO2022065912A1 (ko) | 비올라세인을 포함하는 항콕시듐용 조성물 및 이의 용도 | |
WO2022065911A1 (ko) | 망고스틴을 포함하는 항콕시듐용 조성물 및 이의 용도 | |
WO2022065910A1 (ko) | 스틸벤계 화합물을 포함하는 항콕시듐증 조성물 및 이의 용도 | |
US20220257684A1 (en) | Anti-coccidial phytogenic formulations | |
WO2015065059A1 (ko) | 감태 추출물을 포함하는 어류 바이러스성 출혈성 패혈증에 대한 예방 또는 치료용 조성물 | |
Guang-Fu et al. | RESISTANCE OF FIVE EI MERIA TENELLA ISOLATES TO FOUR ANTICOCCIDIOSIS DRUGS | |
KR100834444B1 (ko) | 물푸레나무로부터 분리된 올레우로페인 화합물을 포함하는톡소플라즈마증 예방 및 치료용 약학조성물 | |
KR20220134191A (ko) | 베르베린(berberine)를 포함하는 콕시듐 예방 또는 치료용 조성물 | |
KR20190050470A (ko) | 봉독을 유효성분으로 포함하는 콕시듐증의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22763629 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18024943 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2023519072 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280006974.3 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023007086 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022763629 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022763629 Country of ref document: EP Effective date: 20231005 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112023007086 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230414 |